At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 76 enrolled
Drug / intervention
BAY3427080 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of the Pharmacokinetics and Safety of NT-814 in Post-Menopausal Women With Vasomotor Symptoms
In Brief
A Phase 2 clinical trial evaluating BAY3427080 and Placebo (for BAY3427080) for Post-menopausal Vasomotor Symptoms. Completed, enrolled 76 participants across 3 sites.
Detailed Summary
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts. Each cohort will comprise of 20 subjects. Subjects will be dosed for 14 days.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-menopausal Vasomotor Symptoms
CountriesUnited States
CollaboratorsNerre Therapeutics Ltd.
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartAug 2016
First PostedAug 2016
Primary CompletionMar 2017
TodayJul 2026
First PostedAug 12, 2016
Enrollment StartAug 1, 2016
Primary CompletionMar 28, 2017
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 9.9 years ago
Interventions
BAY3427080drug
Placebo (for BAY3427080)drug